An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) as a Single Agent and in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of aplitabart+FOLFIRI+bevacizumab.

Start Date23 Sep 2020

Sponsor / Collaborator

IGM Biosciences, Inc.

NCT03803774 / TerminatedPhase 1IIT

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

This phase I trial studies the side effects and best dose of birinapant when given together with intensity modulated re-irradiation therapy (IMRRT) in treating patients with head and neck squamous cell carcinoma that has come back at or near the same place as the original (primary) tumor (locally recurrent). Birinapant may stop the growth of tumor cells by blocking IAP, a protein needed for tumor cell survival. IMRRT uses thin beams of radiation of different intensities that are aimed at the tumor from many angles. This type of re-irradiation therapy reduces the damage to healthy tissue near the tumor. Giving birinapant with IMRRT may lower the chance of head and neck squamous cell carcinoma growing or spreading.

Start Date25 Sep 2019

Sponsor / Collaborator

National Cancer Institute

NCT02756130 / WithdrawnPhase 1/2

A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)

This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as birinapant and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Start Date01 Aug 2018

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+2]

100 Clinical Results associated with Birinapant

100 Translational Medicine associated with Birinapant

100 Patents (Medical) associated with Birinapant

107

Literatures (Medical) associated with Birinapant

05 Jul 2106·Oncotarget

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib

Article

Author: Heinrich, Michael ; Corless, Christopher ; Bauer, Sebastian ; Reis, Anna-Carina ; Marino-Enriquez, Adrian ; Mühlenberg, Thomas ; Podleska, Lars Erik ; Fletcher, Jonathan Alfred ; Treckmann, Jürgen ; Grunewald, Susanne ; Falkenhorst, Johanna ; Schuler, Martin

Gastrointestinal stromal tumors (GIST) exhibit a strong oncogenic dependency on KIT and KIT inhibitors confer long lasting disease stabilization in the majority of patients. Nonetheless, KIT inhibition alone does not cure GIST as a subset of GIST cells evade apoptosis and eventually develop resistance. Inhibitors of Apoptosis Proteins (IAPs) may confer resistance to drug-induced apoptosis. We observed that the mRNA and protein of IAPs XIAP (BIRC4) and survivin (BIRC5) were highly expressed in primary GIST tumors and cell line models. Amplification of the respective gene loci (BIRC2, BIRC3, BIRC4, BIRC5) was detected in 47% of GIST studied by SNP arrays. Whole exome analyses revealed a mutation of SMAC(DIABLO) in a heavily pretreated patient. Both, survivin (rank 62-92/11.194 tested proteins) and XIAP (rank 106-557/11.194) were found to be essential proteins for survival in a synthetic lethality screen. Expression of XIAP and survivin decreased upon KIT inhibition and may play a role in KIT-regulated pro-survival signaling. SMAC-mimetic treatment with LCL161 and TL32711 reduced cIAP1 and XIAP expression. Survivin inhibitor YM155 lead to transcriptional repression of BIRC5/survivin (YM155) and induced apoptosis. Combinational treatment with KIT inhibitors (imatinib, regorafenib) enhanced the proapoptotic effect. These findings support the combination of KIT inhibition with IAP antagonists in GIST.

01 Aug 2024·Mini reviews in medicinal chemistry

SMAC Mimetics for the Treatment of Lung Carcinoma: Present Development and Future Prospects

Article

Author: Bisht, Priya ; Ravichandiran, V ; Murti, Krishna ; Kumar, Nitesh ; Wal, Pranay ; Pandey, Ruchi

Background::

Uncontrolled cell growth and proliferation, which originate from lung tissue often lead to lung carcinoma and are more likely due to smoking as well as inhaled environmental toxins. It is widely recognized that tumour cells evade the ability of natural programmed death (apoptosis) and facilitates tumour progression and metastasis. Therefore investigating and targeting the apoptosis pathway is being utilized as one of the best approaches for decades.

Objective::

This review describes the emergence of SMAC mimetic drugs as a treatment approach, its possibilities to synergize the response along with current limitations as well as future perspective therapy for lung cancer.

Method::

Articles were analysed using search engines and databases namely Pubmed and Scopus.

Result::

Under cancerous circumstances, the level of Inhibitor of Apoptosis Proteins (IAPs) gets elevated, which suppresses the pathway of programmed cell death, plus supports the proliferation of lung cancer. As it is a major apoptosis regulator, natural drugs that imitate the IAP antagonistic response like SMAC mimetic agents/Diablo have been identified to trigger cell death. SMAC i.e. second mitochondria activators of caspases is a molecule produced by mitochondria, stimulates apoptosis by neutralizing/inhibiting IAP and prevents its potential responsible for the activation of caspases. Various preclinical data have proven that these agents elicit the death of lung tumour cells. Apart from inducing apoptosis, these also sensitize the cancer cells toward other effective anticancer approaches like chemo, radio, or immunotherapies. There are many SMAC mimetic agents such as birinapant, BV-6, LCL161, and JP 1201, which have been identified for diagnosis as well as treatment purposes in lung cancer and are also under clinical investigation.

Conclusion::

SMAC mimetics acts in a restorative way in the prevention of lung cancer.

01 Dec 2023·FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Birinapant selectively enhances immunotoxin‐mediated killing of cancer cells conditional on the IAP protein levels within target cells

Article

Author: Hall, Matthew D ; Shen, Min ; Urban, Daniel J ; Bilotta, Maria Teresa ; Antignani, Antonella ; Roth, Jacob S ; FitzGerald, David

Abstract:

Immunotoxins (ITs) target cancer cells via antibody binding to surface antigens followed by internalization and toxin‐mediated inhibition of protein synthesis. The fate of cells responding to IT treatment depends on the amount and stability of specific pro‐apoptotic and pro‐survival proteins. When treated with a pseudomonas exotoxin‐based immunotoxin (HB21PE40), the triple‐negative breast cancer (TNBC) cell line MDA‐MB‐468 displayed a notable resistance to toxin‐mediated killing compared to the epidermoid carcinoma cell line, A431, despite succumbing to the same level of protein synthesis inhibition. In a combination screen of ~1912 clinically relevant and mechanistically annotated compounds, we identified several agents that greatly enhanced IT‐mediated killing of MDA‐MB‐468 cells while exhibiting only a modest enhancement for A431 cells. Of interest, two Smac mimetics, birinapant and SM164, exhibited this kind of differential enhancement. To investigate the basis for this, we probed cells for the presence of inhibitor of apoptosis (IAP) proteins and monitored their stability after the addition of immunotoxin. We found that high levels of IAPs inhibited immunotoxin‐mediated cell death. Further, TNFα levels were not relevant for the combination's efficacy. In tumor xenograft studies, combinations of immunotoxin and birinapant caused complete regressions in MDA‐MB‐468tumor‐bearing mice but not in mice with A431 tumors. We propose that IAPs constitute a barrier to immunotoxin efficacy which can be overcome with combination treatments that include Smac mimetics.

News (Medical) associated with Birinapant

15 Feb 2024

·www.prnewswire.com

MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2023

STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- "The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6 months" October – December Financial summary for the quarter Net turnover amounted to SEK 4.4 (2.3) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -20.1 (-17.9) million. Basic and diluted earnings per share amounted to SEK -0.28 (-0.32) and SEK -0.28 (-0.32) respectively. Cash flow from operating activities amounted to SEK -4.6 (-24.7) million. Cash and cash equivalents at the end of the period amounted to SEK 169.5 (117.4) million. Significant events during the quarter In October, data from an investigator evaluation showed continued promising tumor control with fostrox + Lenvima in HCC. All patients in the phase 2a study had dosed at least two treatment cycles. In October, the Board of Directors announced that Anette Lindqvist is leaving her position as Board Member of Medivir AB due to personal reasons. In October the nomination committee was appointed ahead of the AGM in May 2024. The Nomination Committee consists of Karl Tobieson, appointed by Linc AB, Richard Torgerson, appointed by Nordea Investment Funds, Anders Hallberg, appointed by HealthInvest Partners and Uli Hacksell, Chairman of the Board, Medivir AB. The Q3 report and the subsequent webcast included in-depth interim data from the 18 patients in the phase 1b/2a study who had a minimum follow-up of 12 weeks. These data continued to demonstrate clear patient benefit for the fostrox + Lenvima combination. In November it was announced that the company's interactions with the FDA regarding fostrox's clinical development plan had intensified with a first Type D meeting with a positive response regarding critical elements of the design for the planned phase 2b study. Late November it was announced that the development of an updated formulation of fostrox, suitable for commercial manufacture, had been finalized. In December, Medivir's partner IGM Biosciences, communicated a strategic pipeline cost-saving prioritization that among other things affects IGM's DR-5-agonist, aplitabart, in combination with birinapant, which was licensed in from Medivir in 2021. In December it was announced that Medivir has signed an agreement with Lonza for the manufacture of fostrox drug substance for the planned phase 2b study. In December it was announced that the durable clinical benefit in the ongoing phase 1b/2a study continues to improve, as data become more mature. In December, a rights issue was carried out, through which the company received proceeds of approximately SEK 129 before deduction of costs attributable to the rights issue. January – December Financial summary for the period Net turnover amounted to SEK 7.6 (4.4) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -88.7 (-84.8) million. Basic and diluted earnings per share amounted to SEK -1.48 (-1.59) and SEK -1.48 (-1.59) respectively. Cash flow from operating activities amounted to SEK -59.7 (-101.8) million. Cash and cash equivalents at the end of the period amounted to SEK 169.5 (117.4) million. Events after the end of the period In January, a directed issue to Hallberg Management AB was carried out amounting to approximately SEK 20 million before deduction of issuance costs. In January, positive data from the ongoing phase 1b/2a study in advanced liver cancer (HCC) showing further improved response and time to progression was presented at the ASCO GI Symposium in San Francisco. In January Tango Therapeutics announced that it has dosed the first patient with TNG348, a new USP1-inhibitor from the preclinical USP1 program inlicensed from Medivir in 2020 Conference call for investors, analysts and the media The Year-End Report January - December 2023 will be presented by Medivir's CEO, Jens Lindberg. Time: Thursday, February 15, 2024, at 14.00 (CET). To access the webcast and find information about the teleconference, please klick HERE! The conference call will also be streamed via a link on the website: . The presentation will be available on Medivir's website after completion of the conference. CEO's message Fostrox in combination with Lenvima continues to show improved efficacy for patients with advanced primary liver cancer (HCC). The data presented in January 2024 at the ASCO-GI congress in San Francisco showed a further increase in the proportion of patients who achieve a clinically relevant reduction of their liver tumor and that patients stay on treatment longer with interrupted tumor growth. These data attracted very strong interest, which makes us even more convinced of fostrox's future role in the treatment of HCC and creates the opportunity for a faster route to market. The unmet medical need in the treatment of advanced HCC is significant. Primary liver cancer is the third leading cause of cancer-related deaths. In today's treatment guidelines, an immunotherapy combination (Tecentriq®/Avastin®) is recommended as first-line treatment. However, when this combination has stopped working, there are no approved alternatives for second-line treatment. There is thus a large need for additional treatment options in second-line that attacks the tumor in different ways compared to what Tecentriq and Avastin does. Fostrox is an organ specific, so-called smart chemotherapy, that selectively kills cancer cells in the liver. Together with Lenvima, these two form a unique combination of complementary drugs that have shown promising interim results in an ongoing phase 1b/2a study, including a complete tumor response in one patient. All patients in the study have now had at least 18 weeks of follow-up. The more mature and in-depth data we see from the study, the more convincing the clinical benefit for patients has become. Data from this study was presented at the ASCO GI Congress on January 19, 2024. These results, evaluated by investigators and local radiologists, showed further improvement as the Overall Response Rate (ORR) had increased to 25% (RECIST 1.1), a notably higher percentage than the 5-10% shown in second-line HCC in previous studies. The update also showed continued good tolerability without any new unexpected side effects. At the time of this quarterly report over 40% of patients remain on treatment in the study, and the clinical efficacy keeps improving. The median time to progression has increased further to 6.3 months, compared to 5.1 months at ASCO GI, significantly better than previous studies in second-line HCC. The patient who has benefited the longest remains on treatment after 18 months with partial response and continued shrinking tumor. Our data was met with great interest at ASCO GI, where we had the opportunity to discuss with leading global experts what the fostrox + Lenvima combination could mean for these patients. The discussions confirmed the great need that exists in the second-line treatment of HCC, where patients are today without any approved treatment alternative. With these promising data, fostrox has the opportunity to become the first approved medicinal treatment in a market worth ~2.5 billion USD annually, through a so-called accelerated approval by the regulatory authorities. We have therefore put in a higher gear in 2023 to ensure maximum momentum in fostrox's development program based on this possibility of accelerated approval. In Q4 2023 the development of an updated, commercially adapted formulation of fostrox was completed. In parallel, we have initiated the process with the FDA for a so-called Type C meeting to discuss the final study design of the planned registrational phase 2b study. In conjunction with these measures, we can now also deepen our discussions with potential partners, in accordance with previously communicated plans. We can also note that several of the projects that Medivir has licensed out to collaboration partners is entering clinical stage. In January 2024, Tango Therapeutics initiated a phase 1/2 study and dosed the first patient with TNG348, a USP-1 inhibitor developed from the preclinical USP1 program that was in-licensed from Medivir in 2020. INFEX Therapeutics also intends to initiate phase 1 study in 2024 - with the preclinical program MBLI, previously in-licensed from Medivir. IGM Biosciences has completed the fifth dose escalation cohort in the company's phase 1 study in solid tumors with Medivir's clinical project birinapant in combination with its own DR5 agonist antibody IGM-8444, now called aplitabart. For Medivir, the clinical development of fostrox is clearly in focus. With the promising data showing further improved clinical efficacy compared to expected treatment results in second-line HCC, we are even more confident that fostrox can become an effective liver cancer drug that makes a real difference to patients. I would like to thank old and new shareholders for the trust in our rights issue and for the capital injection that benefited us in the directed share issue. I look forward to keeping you informed of Medivir's continued development. Jens Lindberg Chief Executive Officer For further information, please contact Magnus Christensen, CFO Phone: +46 (0)8 5468 3100 E-mail: [email protected] This report has not been subject to auditors' review. The information was submitted for publication at 08.30 CET on February 15, 2024 The following files are available for download: SOURCE Medivir

Phase 2Phase 1Financial StatementAccelerated ApprovalClinical Result

06 Dec 2023

·www.fiercebiotech.com

IGM, with cash dipping below $390M, cuts headcount 22%, stops blood cancer work to stretch money

IGM ended September with 290 full-time employees. How much money does a biotech need to feel comfortable in today’s market? IGM Biosciences added to evidence that the number is big after the market closed Tuesday, when it revealed a 22% reduction in its headcount and prioritization of its pipeline to make the hundreds of millions in its bank go further. Talking at an investor event last month, IGM CEO Fred Schwarzer gave an upbeat answer to a question about the biotech’s financial footing, telling attendees that it had “plenty of cash to get through into the second half of 2025.” The cash pile stood at $387 million at the end of September. Yet, while IGM has a bank balance to turn some biotechs green with envy, it has decided it needs to cut costs. IGM ended September with 290 full-time employees. The decision to reduce that figure by 22% is part of a set of changes intended to keep IGM going into the second quarter of 2026. Through the changes, IGM is focusing its resources on colorectal cancer and autoimmune diseases. The biotech is halting work on two assets, the CD123xCD3 bispecific IGM-2537 and IL-15xPD-L1 candidate IGM-7354, and cutting the list of the indications targeted by two other molecules. Work on aplitabart in acute myeloid leukemia and in combination with birinapant is stopping, as is development of IGM-2644 in multiple myeloma. In a statement, Schwarzer said IGM is “very encouraged by the clinical and preclinical data that we have generated for the programs” but is halting work in response to “the difficult conditions in the capital markets for our industry.” The changes are intended to narrow IGM’s focus on opportunities with “the most potential to produce significant near-term value,” the CEO said. IGM will continue to study aplitabart, a DR5 agonist, in colorectal cancer, forging toward the goal of enrolling 110 patients in a randomized trial by the end of the first quarter of next year. Development of the CD38xCD3 bispecific IGM-2644 is continuing in autoimmune diseases. IGM aims to file to test the drug candidate in humans next year. Work on the CD20xCD3 bispecific imvotamab is continuing too.

PROTACsFinancial Statement

06 Dec 2023

·www.prnewswire.com

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner, IGM Biosciences, has communicated a strategic pipeline prioritization and reduction of workforce with the key aim of extending its cash runway in a challenging financial climate. In the announcement by IGM, a number of its programs are impacted by this pipeline prioritization, including the combination of IGM's DR-5 agonist, aplitabart and birinapant, which IGM licensed from Medivir in 2021. The combination of aplitabart and birinapant has demonstrated exceptionally strong preclinical synergy across multiple tumor models and has been including patients in the 5th dose escalation cohort, with no dose-limiting toxicities to date. Medivir will discuss with IGM how to maximize the long-term value of birinapant following the announced prioritization. The announcement by IGM has no impact on Medivir's focus and development efforts with its lead program fostroxacitabine bralpamide (fostrox) for the treatment of primary liver cancer (HCC). Medivir continues to maximize the momentum of the fostrox development program as it accelerates a number of critical activities to enable initiation of a pivotal phase 2b study with accelerated approval intent by 2027. If successful outcome of the planned study, fostrox has the potential to become the first approved treatment for HCC patients who have progressed on current first-line standard of care, a market valued at ~$2.5bn annually by 2028. Fostrox is currently being evaluated in an ongoing phase 1b/2a study in combination with Lenvima® in second-line HCC. With all 21 patients now having had minimum 12 weeks follow-up, 81% of the patients show clinical benefit at the first efficacy evaluation with lower than anticipated need for dose modifications due to adverse events. Patients are on average staying longer on treatment than anticipated with ~50% of patients still on treatment and the longest running patient treated for more than 15 months with sustained objective response. For additional information, please contact; Magnus Christensen, CFO, Medivir AB Telephone: +46 8 5468 3100 E-mail: [email protected] About Medivir Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. . The following files are available for download: SOURCE Medivir

Drug ApprovalPhase 2

100 Deals associated with Birinapant

External Link

KEGG	Wiki	ATC	Drug Bank
D10417	-	-	DB11782

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fallopian Tube High Grade Serous Adenocarcinoma	Phase 2	US	TetraLogic Pharmaceuticals Corp.	01 Aug 2018
high grade serous adenocarcinoma of ovary	Phase 2	US	TetraLogic Pharmaceuticals Corp.	01 Aug 2018
Primary Peritoneal High-Grade Serous Adenocarcinoma	Phase 2	US	TetraLogic Pharmaceuticals Corp.	01 Aug 2018
Recurrent Primary Peritoneal Carcinoma	Phase 2	US	TetraLogic Pharmaceuticals Corp.	01 Aug 2018
Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma	Phase 2	US	TetraLogic Pharmaceuticals Corp.	01 Aug 2018
Hepatitis B	Phase 2	AU	Medivir AB	23 Oct 2014
Chronic Myelomonocytic Leukemia	Phase 2	US	TetraLogic Pharmaceuticals Corp.	01 Jun 2014
Chronic Myelomonocytic Leukemia	Phase 2	AU	TetraLogic Pharmaceuticals Corp.	01 Jun 2014
Chronic Myelomonocytic Leukemia	Phase 2	DE	TetraLogic Pharmaceuticals Corp.	01 Jun 2014
Chronic Myelomonocytic Leukemia	Phase 2	ES	TetraLogic Pharmaceuticals Corp.	01 Jun 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01486784 (CTgov)	Phase 1/2	Acute Myeloid Leukemia \| Acute Lymphoblastic Leukemia \| Myelodysplastic Syndromes	27	Birinapant (Phase 1 DL1)	ytwjymqnkr(xrgifrcvil) = epdchzghlj uvwvcslnuy (yeefvpwsfn, bhcmjwumbu - rhvlumujko) View more	-	13 May 2021
				Birinapant (Phase 1 DL-1)	ytwjymqnkr(xrgifrcvil) = kndutaznot uvwvcslnuy (yeefvpwsfn, esoqhrpfhb - ymjodiyvlo) View more
NCT02587962 (BPT-201, CTgov)	Phase 1/2	-	34	birinapant+pembrolizumab (Phase 1 - 5.6 mg)	ytboxnggpx(chipnnwlpq) = zbocgeqpod jhwnyljjvy (getxydqoce, bsofuwmkzj - dgdzsjcijq) View more	-	14 Jan 2021
				birinapant+pembrolizumab (Phase 1 - 11 mg)	ytboxnggpx(chipnnwlpq) = pqhsalbalg jhwnyljjvy (getxydqoce, iilfufdvxk - yfwgxuqkbt) View more
NCT02587962 (BPT-201, ASCO2019)	Phase 1/2	Solid tumor	34	Birinapant + Pembrolizumab	jfxxlmwfjk(ubuspblsgg) = No cases of Bell's palsy were detected. aifxaruilt (ozzmfukdoh ) View more	Positive	26 May 2019
NCT02147873 (ASCO2016)	Phase 2	High Risk Myelodysplastic Syndrome \| Chronic Myelomonocytic Leukemia	118	5-AZA + Birinapant	exbxscnmvq(jrjhbuktvn) = Serious treatment-emergent adverse events (AEs) were higher in the birinapant arm than placebo arm (61.4% vs. 40.8%) ccxrybbtmh (hfbwhfttyf ) View more	Negative	20 May 2016
				Placebo
NCT01681368 (Pubmed \| Cancer) Manual	Phase 2	Ovarian Epithelial Carcinoma	11	birinapant	ghvsxkkazm(aruityedni) = jwyucslxax apvlyjzdam (sntsnzwoly )	Negative	15 Feb 2016
NCT01681368 (CTgov)	Phase 2	Recurrent ovarian cancer \| Peritoneal Neoplasms \| Ovarian Epithelial Carcinoma ... View more	11	Birinapant (TL32711)	vkysuydohl(gqadoqnhdn) = xviivrszdv erbwgeljdx (flcrncfybr, hdgyibivox - znpcxdpzuc) View more	-	03 Feb 2015
NCT01188499 (ASCO2013)	Phase 1	Solid tumor	124	Birinapant	xucoagglem(renfonqbja) = hnxxkoecke mprlznroiq (odnufbqryd )	-	20 May 2013
				Carboplatin/paclitaxel	xucoagglem(renfonqbja) = xcbfcysnev mprlznroiq (odnufbqryd )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis